241 related articles for article (PubMed ID: 28385602)
21. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
Gu Y; Xiao L; Ming Y; Zheng Z; Li W
Int J Oncol; 2016 May; 48(5):1868-76. PubMed ID: 26935808
[TBL] [Abstract][Full Text] [Related]
22. Activity of a sodium-dependent vitamin C transporter (SVCT) in MDCK-MDR1 cells and mechanism of ascorbate uptake.
Luo S; Wang Z; Kansara V; Pal D; Mitra AK
Int J Pharm; 2008 Jun; 358(1-2):168-76. PubMed ID: 18417304
[TBL] [Abstract][Full Text] [Related]
23. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
24. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS.
Qu X; Sheng J; Shen L; Su J; Xu Y; Xie Q; Wu Y; Zhang X; Sun L
PLoS One; 2017; 12(3):e0173712. PubMed ID: 28301876
[TBL] [Abstract][Full Text] [Related]
25. Uptake of ascorbic acid by pancreatic acinar cells is negatively impacted by chronic alcohol exposure.
Subramanian VS; Srinivasan P; Said HM
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C129-35. PubMed ID: 27122159
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of intestinal ascorbic acid uptake by lipopolysaccharide is mediated via transcriptional mechanisms.
Subramanian VS; Sabui S; Moradi H; Marchant JS; Said HM
Biochim Biophys Acta Biomembr; 2018 Feb; 1860(2):556-565. PubMed ID: 29030247
[TBL] [Abstract][Full Text] [Related]
27. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
[TBL] [Abstract][Full Text] [Related]
29. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma.
Wang W; Zhong W; Yuan J; Yan C; Hu S; Tong Y; Mao Y; Hu T; Zhang B; Song G
Oncotarget; 2015 Dec; 6(39):42276-89. PubMed ID: 26474277
[TBL] [Abstract][Full Text] [Related]
30. Ascorbic acid, but not dehydroascorbic acid increases intracellular vitamin C content to decrease Hypoxia Inducible Factor -1 alpha activity and reduce malignant potential in human melanoma.
Fischer AP; Miles SL
Biomed Pharmacother; 2017 Feb; 86():502-513. PubMed ID: 28012930
[TBL] [Abstract][Full Text] [Related]
31. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
32. Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways.
Wandee J; Srinontong P; Prawan A; Senggunprai L; Kongpetch S; Yenjai C; Kukongviriyapan V
Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1929-1940. PubMed ID: 34086099
[TBL] [Abstract][Full Text] [Related]
33. TGR5 promotes cholangiocarcinoma by interacting with mortalin.
Li AD; Xie XL; Qi W; Wang WB; Ma JJ; Zhao DQ; Jiang XY; Chen L; Bai Y; Jiang HQ
Exp Cell Res; 2020 Apr; 389(2):111855. PubMed ID: 31978385
[TBL] [Abstract][Full Text] [Related]
34. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Hu MH; Huang TT; Chao TI; Chen LJ; Chen YL; Tsai MH; Liu CY; Kao JH; Chen KF
Liver Int; 2018 Dec; 38(12):2248-2259. PubMed ID: 29797403
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation.
Lu YX; Wu QN; Chen DL; Chen LZ; Wang ZX; Ren C; Mo HY; Chen Y; Sheng H; Wang YN; Wang Y; Lu JH; Wang DS; Zeng ZL; Wang F; Wang FH; Li YH; Ju HQ; Xu RH
Theranostics; 2018; 8(5):1312-1326. PubMed ID: 29507622
[No Abstract] [Full Text] [Related]
36. Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Yin Y; Zhang M; Dorfman RG; Li Y; Zhao Z; Pan Y; Zhou Q; Huang S; Zhao S; Yao Y; Zou X
Cell Death Dis; 2017 Jun; 8(6):e2856. PubMed ID: 28569784
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
Kabashima A; Hirsova P; Bronk SF; Hernandez MC; Truty MJ; Ilyas SI; Kaufmann SH; Gores GJ
J Hepatol; 2018 Jun; 68(6):1228-1238. PubMed ID: 29408314
[TBL] [Abstract][Full Text] [Related]
38. Limited Association Between Ascorbate Concentrations and Vitamin C Transporters in Renal Cell Carcinoma Cells and Clinical Samples.
Wohlrab C; Vissers MCM; Burgess ER; Nonis M; Phillips E; Robinson BA; Dachs GU
Cell Physiol Biochem; 2021 Oct; 55(5):553-568. PubMed ID: 34599650
[TBL] [Abstract][Full Text] [Related]
39. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.
Boulter L; Guest RV; Kendall TJ; Wilson DH; Wojtacha D; Robson AJ; Ridgway RA; Samuel K; Van Rooijen N; Barry ST; Wigmore SJ; Sansom OJ; Forbes SJ
J Clin Invest; 2015 Mar; 125(3):1269-85. PubMed ID: 25689248
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of antitumor effects of bromelain and papain in human cholangiocarcinoma cell lines.
Müller A; Barat S; Chen X; Bui KC; Bozko P; Malek NP; Plentz RR
Int J Oncol; 2016 May; 48(5):2025-34. PubMed ID: 26935541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]